Kenvue Inc. $KVUE Stock Position Lowered by Mirabella Financial Services LLP

Mirabella Financial Services LLP decreased its position in Kenvue Inc. (NYSE:KVUE) by 55.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,615 shares of the company’s stock after selling 84,298 shares during the quarter. Mirabella Financial Services LLP’s holdings in Kenvue were worth $1,385,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of KVUE. TIAA Trust National Association bought a new position in shares of Kenvue during the 1st quarter valued at about $214,000. Atria Wealth Solutions Inc. lifted its stake in Kenvue by 48.0% during the first quarter. Atria Wealth Solutions Inc. now owns 27,022 shares of the company’s stock valued at $648,000 after purchasing an additional 8,765 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its holdings in Kenvue by 16.6% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 4,500 shares of the company’s stock worth $108,000 after buying an additional 642 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Kenvue by 34.2% in the first quarter. Goldman Sachs Group Inc. now owns 19,670,179 shares of the company’s stock worth $471,691,000 after buying an additional 5,011,431 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after buying an additional 10,600,682 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE opened at $16.97 on Friday. The company has a market capitalization of $32.51 billion, a PE ratio of 22.63 and a beta of 0.60. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The company’s 50 day moving average price is $16.08 and its 200 day moving average price is $19.40. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. Kenvue’s dividend payout ratio is currently 110.67%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on KVUE shares. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. JPMorgan Chase & Co. dropped their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Citigroup cut their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. Finally, Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus target price of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.